Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade D 89.62 -1.53% -1.39
CELG closed down 1.53 percent on Thursday, April 19, 2018, on 55 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: May 4

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical CELG trend table...

Date Alert Name Type % Chg
Apr 19 Fell Below 50 DMA Bearish 0.00%
Apr 19 Stochastic Sell Signal Bearish 0.00%
Apr 19 Upper Bollinger Band Walk Strength 0.00%
Apr 19 Multiple of Ten Bearish Other 0.00%
Apr 19 Overbought Stochastic Strength 0.00%
Apr 18 Shooting Star Candlestick Bearish -1.53%
Apr 18 Lizard Bearish Bearish Day Trade Setup -1.53%
Apr 18 Narrow Range Bar Range Contraction -1.53%
Apr 18 NR7 Range Contraction -1.53%
Apr 18 Upper Bollinger Band Walk Strength -1.53%

Older signals for CELG ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 147.17
52 Week Low 84.25
Average Volume 7,137,560
200-Day Moving Average 113.3185
50-Day Moving Average 90.4579
20-Day Moving Average 88.4815
10-Day Moving Average 89.345
Average True Range 2.4307
ADX 17.4
+DI 17.95
-DI 22.44
Chandelier Exit (Long, 3 ATRs ) 84.6779
Chandelier Exit (Short, 3 ATRs ) 91.5421
Upper Bollinger Band 91.9674
Lower Bollinger Band 84.9956
Percent B (%b) 0.66
BandWidth 7.879387
MACD Line -0.0924
MACD Signal Line -0.5862
MACD Histogram 0.4938
Fundamentals Value
Market Cap 70.11 Billion
Num Shares 782 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 27.75
Price-to-Sales 6.42
Price-to-Book 9.26
PEG Ratio 0.67
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 93.42
Resistance 3 (R3) 93.72 92.76 92.78
Resistance 2 (R2) 92.76 91.79 92.61 92.57
Resistance 1 (R1) 91.19 91.20 90.71 90.89 92.36
Pivot Point 90.23 90.23 89.99 90.08 90.23
Support 1 (S1) 88.66 89.26 88.18 88.36 86.88
Support 2 (S2) 87.70 88.67 87.55 86.67
Support 3 (S3) 86.13 87.70 86.46
Support 4 (S4) 85.83